Sten H Vermund1, Katherine L Allen, Quarraisha Abdool Karim. 1. Institute for Global Health and Department of Pediatrics at Vanderbilt University School of Medicine, 2215 Garland Drive (319 Light Hall), Nashville, TN 37232-0242, USA. sten.vermund@vanderbilt.edu
Abstract
PURPOSE OF REVIEW: We review the current state of evidence-based prevention strategies for reducing sexual transmission of HIV. The combined programmatic and scientific efforts through 2008 to reduce sexual transmission of HIV have failed to reduce substantially the global pandemic. RECENT FINDINGS: Prevention interventions to reduce HIV infection target behavioral, biomedical, and structural risk factors. Some of these prevention strategies have been evaluated in randomized clinical trials (RCTs) with HIV seroincidence endpoints. When RCTs are not feasible, a variety of observational and quasiexperimental research approaches can provide insight as to program effectiveness of specific strategies. Only five RCTs have demonstrated a notable decrease in sexually acquired HIV incidence. These include the Mwanza study of syndromic management of sexually transmitted diseases and three male circumcision trials in East Africa; a microbicide trial reported in 2009 shows substantial promise for the efficacy of PRO 2000 (0.5% gel). SUMMARY: The combined programmatic and scientific efforts to reduce sexual transmission of HIV have made incremental progress. New prevention tools are needed to stem the continued spread of HIV, though microbicides and vaccines will take many more years to develop, test, and deploy. Combination strategies of existing modalities should be tested to evaluate the potential for more proximate prevention benefits.
PURPOSE OF REVIEW: We review the current state of evidence-based prevention strategies for reducing sexual transmission of HIV. The combined programmatic and scientific efforts through 2008 to reduce sexual transmission of HIV have failed to reduce substantially the global pandemic. RECENT FINDINGS: Prevention interventions to reduce HIV infection target behavioral, biomedical, and structural risk factors. Some of these prevention strategies have been evaluated in randomized clinical trials (RCTs) with HIV seroincidence endpoints. When RCTs are not feasible, a variety of observational and quasiexperimental research approaches can provide insight as to program effectiveness of specific strategies. Only five RCTs have demonstrated a notable decrease in sexually acquired HIV incidence. These include the Mwanza study of syndromic management of sexually transmitted diseases and three male circumcision trials in East Africa; a microbicide trial reported in 2009 shows substantial promise for the efficacy of PRO 2000 (0.5% gel). SUMMARY: The combined programmatic and scientific efforts to reduce sexual transmission of HIV have made incremental progress. New prevention tools are needed to stem the continued spread of HIV, though microbicides and vaccines will take many more years to develop, test, and deploy. Combination strategies of existing modalities should be tested to evaluate the potential for more proximate prevention benefits.
Authors: L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: D D Celentano; K E Nelson; C M Lyles; C Beyrer; S Eiumtrakul; V F Go; S Kuntolbutra; C Khamboonruang Journal: AIDS Date: 1998-03-26 Impact factor: 4.177
Authors: Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya Journal: J Infect Dis Date: 2006-11-03 Impact factor: 5.226
Authors: A Kamali; M Quigley; J Nakiyingi; J Kinsman; J Kengeya-Kayondo; R Gopal; A Ojwiya; P Hughes; L M Carpenter; J Whitworth Journal: Lancet Date: 2003-02-22 Impact factor: 79.321
Authors: Paul M Pronyk; Julia C Kim; Tanya Abramsky; Godfrey Phetla; James R Hargreaves; Linda A Morison; Charlotte Watts; Joanna Busza; John Dh Porter Journal: AIDS Date: 2008-08-20 Impact factor: 4.177
Authors: Godfrey Kigozi; Ronald H Gray; Maria J Wawer; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Renee Ridzon; Pius Opendi; Victor Sempijja; Absolom Settuba; Denis Buwembo; Valerian Kiggundu; Margaret Anyokorit; James Nkale; Nehemia Kighoma; Blake Charvat Journal: PLoS Med Date: 2008-06-03 Impact factor: 11.069
Authors: Sten H Vermund; Sally L Hodder; Jessica E Justman; Beryl A Koblin; Timothy D Mastro; Kenneth H Mayer; Darrell P Wheeler; Wafaa M El-Sadr Journal: Clin Infect Dis Date: 2010-05-15 Impact factor: 9.079
Authors: Xiangrong Kong; Godfrey Kigozi; Fred Nalugoda; Richard Musoke; Joseph Kagaayi; Carl Latkin; Robert Ssekubugu; Tom Lutalo; Betty Nantume; Iga Boaz; Maria Wawer; David Serwadda; Ronald Gray Journal: Am J Epidemiol Date: 2012-10-24 Impact factor: 4.897
Authors: Carolyn M Audet; Janeen Burlison; Troy D Moon; Mohsin Sidat; Alfredo E Vergara; Sten H Vermund Journal: BMC Int Health Hum Rights Date: 2010-06-08